Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants

Oncogene volume 25, pages 6595–6603 (2006)Cite this article

Abstract

Retroviral integration mutagenesis and treatment with the frameshift mutagen ICR191 were used to transform v-H-ras expressing PB-3c cells to interleukin-3 (IL-3) independence. Six clones displayed viral integrations into the 3′ region of the IL-3 gene thus acting post-transcriptionally by disrupting the AU-rich instability element. Two clones contained reverse orientation integration into the raf-1 gene revealing an enhancer insertion mechanism. Growth by this mechanism was sensitive to the Raf-1 inhibitor BAY 43-9006 and the Mek inhibitor U0126. Following treatment with ICR191, IL-3-independent clones were recovered and studied by cell fusion. With 21/22 clones, IL-3 independence resulted from a recessive mechanism as cellular hybrids with parental cells reverted to IL-3 dependence. Recessive clone D2c displayed increased phospho-Erk1/2 levels and was growth sensitive to U0126, but not to BAY43-9006. The single dominant clone, D5a, showed no signs of mitogen-activated protein kinases pathway activation but displayed constitutive phosphorylation of Stat5. We conclude that PB-3c has several options to acquire IL-3 growth autonomy involving transcriptional or post-transcriptional mechanisms affecting the distal regulators Erk or Stat5. The reported panel of independent dominant and recessive transformants should provide a useful tool for inhibitor profiling.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Algate PA, McCubrey JA . (1993). Oncogene 8: 1221–1232.

  • Andrejauskas E, Moroni C . (1989). EMBO J 8: 2575–2581.

  • Benjamin D, Colombi M, Moroni C . (2004). Nucleic acids research 32: e89.

  • Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H et al. (2000). Oncogene 19: 526–536.

  • Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA et al. (1999). Leukemia 13: 1109–1166.

  • D'Andrea R, Rayner J, Moretti P, Lopez A, Goodall GJ, Gonda TJ et al. (1994). Blood 83: 2802–2808.

  • Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. (1996). Nat Med 2: 561–566.

  • Gough NM . (1988). Analytical biochemistry 173: 93–95.

  • Hannemann J, Hara T, Kawai M, Miyajima A, Ostertag W, Stocking C . (1995). Mol Cell Biol 15: 2402–2412.

  • Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H et al. (2000). Oncogene 19: 624–631.

  • Hirsch HH, Nair AP, Moroni C . (1993). J Exp Med 178: 403–411.

  • Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M et al. (2000). Leukemia 14: 642–656.

  • Ihle JN, Lee JC, Rebar L . (1981). J Immunol 127: 2565–2570.

  • Jiang X, Ng E, Yip C, Eisterer W, Chalandon Y, Stuible M et al. (2002). Blood 100: 3731–3740.

  • Joung YH, Park JH, Park T, Lee CS, Kim OH, Ye SK et al. (2003). Exp Mol Med 35: 350–357.

  • Liu CB, Itoh T, Arai K, Watanabe S . (1999). J Biol Chem 274: 6342–6349.

  • McCormack MP, Gonda TJ . (1997). Blood 90: 1471–1481.

  • McCubrey JA, Shelton JG, Steelman LS, Franklin RA, Sreevalsan T, McMahon M. . (2004). Oncogene 23: 7810–7820.

  • McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA et al. (1998). Leukemia 12: 1903–1929.

  • Morita S, Kojima T, Kitamura T . (2000). Gene Ther 7: 1063–1066.

  • Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A . (1995). EMBO J 14: 1166–1175.

  • Nagata Y, Todokoro K . (1996). Biochem Biophys Res Commun 221: 785–789.

  • Nair AP, Diamantis ID, Conscience JF, Kindler V, Hofer P, Moroni C . (1989). Mol Cell Biol 9: 1183–1190.

  • Nosaka T, Kitamura T . (2002). Exp Hematol 30: 697–702.

  • Onishi M, Kinoshita S, Morikawa Y, Shibuya A, Phillips J, Lanier LL et al. (1996a). Exp Hematol 24: 324–329.

  • Onishi M, Mui AL, Morikawa Y, Cho L, Kinoshita S, Nolan GP et al. (1996b). Blood 88: 1399–1406.

  • Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M et al. (1998). Mol Cell Biol 18: 3871–3879.

  • Overell RW, Watson JD, Gallis B, Weisser KE, Cosman D, Widmer MB . (1987). Mol Cell Biol 7: 3394–3401.

  • Perkins GR, Marshall CJ, Collins MK . (1996). Blood 87: 3669–3675.

  • Piao X, Bernstein A . (1996). Blood 87: 3117–3123.

  • Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW et al. (2003). Oncogene 22: 2478–2492.

  • Shounan Y, Miller M, Symonds G . (1995). Exp Hematol 23: 492–499.

  • Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA . (2004). Leukemia 18: 189–218.

  • Stoecklin G, Colombi M, Raineri I, Leuenberger S, Mallaun M, Schmidlin M et al. (2002). EMBO J 21: 4709–4718.

  • Stoecklin G, Gross B, Ming XF, Moroni C . (2003). Oncogene 22: 3554–3561.

  • Stoecklin G, Hahn S, Moroni C . (1994). J Biol Chem 269: 28591–28597.

  • Testa U, Riccioni R, Diverio D, Rossini A, Lo Coco F, Peschle C . (2004). Leukemia 18: 219–226.

  • Wodnar-Filipowicz A, Heusser CH, Moroni C . (1989). Nature 339: 150–152.

Download references

Acknowledgements

We thank Dr Don Benjamin and Bernd Rattenbacher for discussion and comments on the manuscript.

Author information

Author notes

  1. K F Kiser and M Colombi: These two authors contributed equally to this work.

Authors and Affiliations

  1. Department of Clinical-Biological Sciences, Institute for Medical Microbiology, University of Basel, Basel, Switzerland

    K F Kiser, M Colombi & C Moroni

Authors
  1. K F Kiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Colombi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Moroni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Moroni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kiser, K., Colombi, M. & Moroni, C. Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants. Oncogene 25, 6595–6603 (2006). https://doi.org/10.1038/sj.onc.1209673

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209673

Keywords

This article is cited by

Search

Advanced search

Quick links